Tilemetin 60mg Injection

Introduction

Tilemetin is a prescription medication that contains the active ingredient Dehydroemetine. This medication is used for the treatment of certain parasitic infections in the body. It is available in the form of an injection and is generally administered under medical supervision.

Uses

Tilemetin is primarily prescribed for the treatment of amoebiasis, a condition caused by a parasitic infection called Entamoeba histolytica. It is also used in the treatment of other parasitic infections, such as giardiasis and trichomoniasis.

Dosage and Administration

The dosage of Tilemetin may vary depending on the specific condition being treated and the patient’s individual response to the medication. Follow the instructions provided by your healthcare provider.

Tilemetin is typically administered by a healthcare professional in a clinical setting. The injection is given into a muscle (intramuscular injection) or directly into a vein (intravenous injection). The frequency and duration of treatment will be determined by your healthcare provider.

Mechanism of Action

Dehydroemetine, the active ingredient in Tilemetin, works by interfering with the growth and replication of the parasites causing the infection. It inhibits certain enzymes in the parasites, leading to their destruction.

Side Effects

Common side effects may include pain or discomfort at the injection site, nausea, vomiting, and diarrhea. These side effects are usually mild and temporary.

Serious side effects are rare but can occur. If you experience any of the following, seek medical attention immediately: severe allergic reactions (such as rash, itching, swelling, dizziness, or difficulty breathing), severe stomach pain, or persistent diarrhea.

Drug Interactions

inform your healthcare provider about all the medications you are taking, including prescription, over-the-counter, and herbal products. Certain medications may interact with Tilemetin, potentially affecting its effectiveness or increasing the risk of side effects. Be sure to discuss any potential drug interactions with your healthcare provider.

Precautions

Before using Tilemetin, inform your healthcare provider if you have any known allergies or medical conditions. Disclose any medications you are currently taking to avoid potential interactions.

Tilemetin should be used with caution in pregnant or breastfeeding women, as its safety in these populations has not been established. Your healthcare provider can help assess the potential benefits and risks of using this medication during pregnancy or while breastfeeding.

Storage

Tilemetin should be stored at the recommended temperature as specified on the packaging. Keep this medication out of the reach of children and away from direct sunlight or heat sources. Do not use the medication if it has expired or if the packaging is damaged.

Patient Tips

• Follow the dosage instructions provided by your healthcare provider and complete the full course of treatment, even if you start feeling better before the treatment is completed.
• If you have any questions or concerns about the medication or its administration, don’t hesitate to consult your healthcare provider or pharmacist.
• Keep all follow-up appointments with your healthcare provider to monitor your progress and ensure the medication is working effectively.
• If you experience any concerning side effects or have any questions, contact your healthcare provider for guidance.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Panwar P, Burusco KK, Abubaker M, Matthews H, Gutnov A, Fernández-Álvaro E, Bryce RA, Wilkinson J, Nirmalan N. Lead Optimization of Dehydroemetine for Repositioned Use in Malaria. Antimicrob Agents Chemother. 2020 Mar 24;64(4):e01444-19. doi: 10.1128/AAC.01444-19. Print 2020 Mar 24. [Accessed 2 Jun. 2024] Available at:
• Zulfiqar H, Mathew G, Horrall S. Amebiasis. 2023 Jun 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. [Accessed 20 Jun. 2024] Available at:
• Abd-Rabbo H. Dehydroemetine in chronic leukaemia. Lancet. 1966 May 21;1(7447):1161-2. doi: 10.1016/s0140-6736(66)91188-3. [Accessed 22 Jun. 2024] Available at:
• SALEM HH, ABD-RABBO H. DEHYDROEMETINE IN BILHARZIASIS. Lancet. 1963 Nov 23;2(7317):1120. doi: 10.1016/s0140-6736(63)92894-0. [Accessed 3 Jun. 2024] Available at: